What's Happening?
OrganaBio has opened a new facility in San Diego dedicated to the isolation and cryopreservation of peripheral blood mononuclear cells (PBMCs), significantly reducing processing time to just three to four hours. This development addresses a common bottleneck
in cell and gene therapy by ensuring high cell viability and functional integrity. The facility, part of OrganaBio's acquisition of Excellos Labs, allows for local processing, eliminating the need to ship live materials across the country. This rapid processing is crucial for maintaining the quality of PBMCs, which are foundational in immunotherapies and vaccine development. The San Diego lab reports high PBMC viability and recovery rates, attributed to rapid cryopreservation and standardized procedures.
Why It's Important?
The establishment of OrganaBio's San Diego facility is a strategic advancement for the cell and gene therapy industry, particularly in the U.S. By reducing the time between PBMC collection and cryopreservation, the facility enhances the quality and reliability of starting materials for biotherapeutic developers. This local processing capability not only improves cell viability but also reduces supply chain risks associated with transportation and cold-chain logistics. The facility's presence in a major cell therapy hub like San Diego supports the region's clinical-stage biotherapeutic developers by providing faster and more reliable access to high-quality PBMCs. This development is expected to streamline manufacturing timelines and support the growth of cell therapy innovations.
What's Next?
OrganaBio plans to expand its services, including clinical trial and manufacturing services, to meet the growing demand for high-quality PBMCs. The company is also exploring opportunities to enter additional markets with strong population growth and diversity, where professionalized PBMC isolation services are lacking. This expansion could further enhance the availability and quality of cell therapy materials, supporting the broader biotherapeutic industry. As OrganaBio continues to onboard new customers and deepen existing relationships, the company is poised to play a significant role in advancing cell and gene therapy innovations.
